Voyager SPAC Faces Near-Total Redemptions: 99.67% of Shares Redeemed Ahead of VERAXA Biotech Merger
VACH sits 15% above its 52-week low of $10.06.
Summary
Voyager Acquisition Corp. announced that an overwhelming 99.67% of its Class A ordinary shares, totaling 25,217,315 shares, were redeemed by holders in connection with its business combination with VERAXA Biotech AG. This follows the approval of the merger by VERAXA Biotech shareholders on February 27, 2026, making the redemption results the final critical step before closing. The extremely high redemption rate means only approximately $885,556 will remain in Voyager's trust account, leaving minimal capital for VERAXA Biotech AG post-merger. This significantly diminishes the financial benefit of the SPAC transaction for VERAXA and will result in a very small public float for the combined entity, which is expected to trade as VRXA. Traders should anticipate potential liquidity issues and high volatility for the combined entity due to the drastically reduced capital and public float.
At the time of this announcement, VACH was trading at $11.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $336.2M. The 52-week trading range was $10.06 to $10.99. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.